S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

SLRX Salarius Pharmaceuticals Inc

0.475

-0.006 (-1.25%)

After Hours

Last Updated: 15:02:01

Delayed by 15 minutes

Salarius Pharmaceuticals readies stock offering

To read the full story on Seeking Alpha, click here.

Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Salarius Pharmaceuticals Charts.

Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Salarius Pharmaceuticals Charts.

Salarius Pharmaceuticals Inc News

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Friday 22 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 February 2024 (2 months ago) • Edgar (US Regulatory)

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Tuesday 16 January 2024 (4 months ago) • GlobeNewswire Inc.

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Wednesday 3 January 2024 (4 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 9 November 2023 (6 months ago) • Edgar (US Regulatory)

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Tuesday 7 November 2023 (6 months ago) • GlobeNewswire Inc.

Form SC 13D - General statement of acquisition of beneficial ownership
Friday 27 October 2023 (6 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 6 September 2023 (8 months ago) • Edgar (US Regulatory)

More Salarius Pharmaceuticals Inc News Articles

Greene Concepts (PK)

Moon Equity (PK)

Blue Line Protection (PK)

Globestar Therapeutics (PK)

TPT Global Tech (CE)

Houston Natural Resources (PK)

Kraig Biocraft Laborator... (QB)

Movement Industries (PK)

FuelCell Energy

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions